Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Would it be possible to give the dose sublingually or as a patch after the onset of sleep at a prespecified time to see if it would extend the sleep? & I am wondering if the dose at 12mg is too high.
Also placing a voice recorder near the subject should give redundancy & robustness to the data capture process. The audio can be viewed graphically and peaks in db levels may be overlayed/matched with actigraph data.
It's interesting that after the registration, 93 children did not meet inclusion criteria. This, if I understand clearly, was because it included children that responded well with non-pharmacological intervention (booklet of advice on previously trialed and standardized sleep behavior treatment).
That means it would prove beneficial to use non-pharmacological interventions more proactively in clinical practice.
1. Gringras P ,Gamble C ,Jones AP ,Wiggs L ,Williamson PR ,Sutcliffe A ,et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012;345:e6664
Re: Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial
Response to "Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial" (1).
______________________________________________________________________________________
Would it be possible to give the dose sublingually or as a patch after the onset of sleep at a prespecified time to see if it would extend the sleep? & I am wondering if the dose at 12mg is too high.
Also placing a voice recorder near the subject should give redundancy & robustness to the data capture process. The audio can be viewed graphically and peaks in db levels may be overlayed/matched with actigraph data.
It's interesting that after the registration, 93 children did not meet inclusion criteria. This, if I understand clearly, was because it included children that responded well with non-pharmacological intervention (booklet of advice on previously trialed and standardized sleep behavior treatment).
That means it would prove beneficial to use non-pharmacological interventions more proactively in clinical practice.
______________________________________________________________________________________
1. Gringras P ,Gamble C ,Jones AP ,Wiggs L ,Williamson PR ,Sutcliffe A ,et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ 2012;345:e6664
Competing interests: No competing interests